Report Date: Tuesday, August 4, 2026, 8:00 a.m. ET | Prior Close (Aug 3): ~$118.75
Leidos heads into this print in an unusual spot: the underlying business has been executing well and guidance has actually gone up, yet the stock has been cut roughly in half from its January highs (~$198) to a June low near $100, before staging a partial recovery back into the $110s. Investors will be looking for signs of whether the recent bounce is the start of a durable re-rating or a dead-cat bounce ahead of a genuinely tricky quarter.
Why the stock cratered: The proximate trigger was news that the Defense Health Agency plans to end Leidos' decade-long role as lead systems integrator on the MHS GENESIS electronic health record program. As one report noted, DHA plans to transition Philips and Amwell away from Leidos' management by the end of July 2026, with Oracle Health following by November 2026 and Henry Schein and Solventum by July 2027. DHA cited reduced cost transparency, duplicative layers of management and administration, limited government visibility into pricing structures, and constraints on the government's ability to directly manage performance as reasons for moving to direct, sole-source relationships with the underlying vendors. This hit directly at Health, Leidos' highest-margin segment (~24% operating margin), and triggered a wave of sell-side downgrades: Jefferies cut its rating to Hold, "expressing concern that the company's profit margins could be difficult to maintain," while Bank of America downgraded to Neutral from Buy "on the belief that pressure is building on its 'once blooming' healthcare portfolio." Price targets were slashed across the Street — BofA to $125 (from $200), Jefferies to $110 (from $140), Citi to $138, JPMorgan to $160, Goldman Sachs to $152 — even as several of these firms kept constructive ratings, arguing the sell-off had overshot the fundamental change.
By late June the stock had fallen as much as ~45% from its 52-week high, trading around 10x trailing earnings versus a five-year average multiple in the high-teens/low-20s. Shares have since recovered roughly 15-18% off the lows, helped in part by an AI/data-modernization partnership announcement in late June and a broader stabilization in sentiment, but the stock remains well below the ~$151-167 average analyst price target and roughly 35% below Street consensus fair value heading into the print.
Leidos' Q1 (reported May 5) was strong on the surface: revenue of $4.4 billion, up 4% (3% organic), non-GAAP EPS of $3.13 (up 5% YoY), and adjusted EBITDA margin of 14.0%. Management raised full-year guidance — revenue to $18.0-18.4B, non-GAAP EPS to $12.10-12.50, and operating cash flow to ~$1.8B — but the raise was driven almost entirely by the accretive, quickly-closed Entrust (energy infrastructure) acquisition rather than upside in the base business.
Critically, management explicitly flagged Q2 as the low point of the year. CFO Chris Cage told investors: "we see Q2 as the likely low point this year in revenue growth and margin. At this point, we view Q1 revenue overperformance as a pull-forward from the second quarter as opposed to a notable market reacceleration, which we still expect in the second half of the year." He added that Q2 would look "more similar to Q1, maybe a small step down on run rate and profitability building to the back half of the year." Management also disclosed a below-target book-to-bill of 0.8x for the quarter (1.1x trailing-twelve-months) and warned that near-term growth investments — including ramp costs on the new Military OneSource award — would weigh on Q2 profitability, with no repeat of Q1's one-time $15 million insurance reimbursement.
| Metric | Street Consensus | Q2 2025 Actual |
|---|---|---|
| Revenue | ~$4.42-4.43B | $4.3B |
| Non-GAAP diluted EPS | ~$2.90-2.91 | $3.21 |
| FY26 EPS (full year) | ~$12.26-12.30 | — |
| FY26 Revenue (full year) | ~$18.1-18.2B | — |
Analysts are modeling revenue growth of roughly 3-4.5% year-over-year — an acceleration from the prior year's growth rate mostly reflecting the Entrust acquisition — but a year-over-year EPS decline of ~9-10%, since Q2 2025 was a record quarter (adjusted EBITDA margin of 15.2%, non-GAAP EPS of $3.21, up 22% YoY at the time). Leidos has beaten EPS estimates in each of the last several quarters (an average surprise of roughly 13 bps over the trailing four quarters per Benzinga data), so the bar, while lower than last year, isn't necessarily a stretch.
Health segment guidance and the DHA/MHS GENESIS transition. This is the single biggest overhang. Investors will want explicit quantification of revenue/margin impact for the balance of 2026 and into 2027, given Philips/Amwell transition off Leidos by end of July (essentially now) and Oracle Health by November. Watch whether management narrows or reaffirms its prior characterization of Health as a "modest reset this year with a growth trajectory in the future," and whether new wins (Military OneSource, My Service Treatment Record pilot) are framed as offsetting the integrator role loss.
VBA disability exam business. Volumes were described as remaining high in Q1, with an Industry Day scheduled for late May to discuss the program's future structure. Any update on exam volumes, competitive dynamics (four-vendor IDIQ), and margin durability in this cash-generative franchise will matter for Health segment credibility.
Whether Q2 plays out as the guided "low point." Sequential revenue/margin softness was explicitly pre-announced; the market will focus less on the magnitude of the dip and more on management's conviction around a second-half reacceleration (Q3/Q4 step-up) — and whether the framing changes at all given the DHA news that emerged after the Q1 call.
Defense segment margin recovery. Q1 Defense margin fell to 8.3% (non-GAAP) from 9.8% a year ago due to a fixed-price development program delay (Space Wide Field of View Tranche 1). Management pointed to ramping, better-margin programs (IFPC, PAMS, ABAD/ALPS) as the offset — look for evidence this is materializing.
Book-to-bill and pipeline conversion. Q1's 0.8x book-to-bill was soft; management guided to a pickup in awards through the year. Watch for progress against the ~$8B next-12-month Defense Tech pipeline, the $24B cyber pipeline (Kudu), and the refreshed ~$10B Entrust order pipeline.
Entrust integration and accretion. Entrust closed in March and was called "immediately accretive"; investors will want an update on synergy capture, cross-sell wins (e.g., the first energy generation plant RFP, Canada's largest battery storage design win), and whether the deal's contribution to guidance is tracking or ahead.
Security Products (SES) joint venture with Analogic. Expected to close in the back half of 2026; timing and any changes to deal terms or expected equity-method income contribution will be relevant, along with confirmation that SES/Industrial Automation remain classified as held-for-sale.
Capital deployment and leverage. Gross leverage stood at 2.6x at Q1-end following debt-funded Entrust financing; $200M+ was repurchased in Q1. Watch buyback pace, commercial paper paydown, and whether the elevated CapEx plan (up to $350M for the year, though only $31M spent in Q1) is being deployed faster in Q2/H2.
Full-year guidance: reaffirm, raise, or trim? Given the DHA development and the pre-announced Q2 softness, a straight reaffirmation of the $18.0-18.4B revenue / $12.10-12.50 EPS range would likely be read as reassuring; any language suggesting Health-related guidance risk could reignite the negative narrative that drove the June sell-off.
Even after the recent bounce, LDOS trades at a meaningfully discounted multiple to history and peers — around 10x trailing earnings versus a five-year average closer to 18-20x — with a consensus analyst price target in the $150-167 range implying substantial upside from current levels. The bull case (articulated by several analysts even amid downgrades) rests on Leidos' debt-servicing capacity, cash generation, and diversified portfolio being able to absorb the DHA integrator loss without a structural change to the long-term growth story; the bear case is that this is the first crack in a healthcare/health-IT franchise that has been a key margin driver, with further contract-specific risk still to be quantified.
Going into Q2, the operative debate isn't really about the headline revenue/EPS print — management pre-announced a soft quarter, and estimates already reflect that. The real swing factor is management's tone and any hard numbers on the Health segment following the DHA/MHS GENESIS integrator decision, combined with whether the "second-half reacceleration" narrative from the Q1 call still holds. A confident reaffirmation of full-year guidance with concrete color on Health, Defense margin recovery, and pipeline conversion could support further stabilization in the stock; any incremental negative revision to Health outlook, or a softer-than-expected book-to-bill, risks reopening the wounds from June's ~40% drawdown.